FDA Approves TNKase for Acute Ischemic Stroke

FDA Approves TNKase for Acute Ischemic Stroke

THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

FDA approves clot-dissolving agent for treatment of acute ischemic stroke

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second IV bolus administration

Antiplatelet Therapy vs. Anticoagulation in Cervical Artery Dissection: Evolving Evidence and Ongoing Questions

.flex_column.av-pxfofs-f8cffa300d0abe60229a0238b37e998b{ border-radius:0px 0px 0px 0px; padding:0px 0px 0px 0px; } 07/03/2025/in ESO, Stroke Research /by Carine Legio Authors: Dr. Alexandru Dimancea X: @DimanceaAlex Dr. Raoul Pop X: @RaoulPop25 Recent research efforts in the field of stroke interventional treatment have focused on efficacy and safety of mechanical thrombectomy (MT) in medium vessel occlusions (MeVO)-acute ischaemic stroke (AIS)…

A 'PACT' to monitor stroke in real-time

Every year, millions of people die from stroke. In order to win against this disease which occurs the moment when a blood vessel is blocked in brain, a research team from the Pohang University of Science & Technology (Postech) made a breakthrough with a new technology combining light and sound.